Janssen Pharma, Russia's NewVac To Develop Cancer-Treatment Drug
This article was originally published in PharmAsia News
Janssen Pharmaceuticals and NewVac have signed an agreement to share development and marketing rights for the U.S. drug maker's quisinostat for treating solid tumors along with standard care in Eastern Europe.
You may also be interested in...
The median review time for novel agents at CDER hasn’t changed in five years. Our infographic offers a look at the tortoises and hares (all of them winners because they got approved).
Cost increases initially spurred by supply chain disruptions by COVID-19 pandemic have been noted by businesses across consumer product industries since soon after novel coronavirus spread accelerated in early 2020. More recently, OTC drug, nutritional supplement and personal care product providers began noting inflation’s influence on costs.
On this week’s podcast, Medtech Insight's Reed Miller, Marion Webb and Barnaby Pickering provide a recap of our J.P. Morgan Health Care conference coverage including Abbott, Dexcom, Zimmer Biomet and Nuvasive and spotlight Scottish company PneumoWave.